These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 37493986)

  • 1. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
    Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
    Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of circulating tumour DNA in terms of prognosis prediction in Chinese follicular lymphoma patients.
    Zhao M; Li Q; Yang J; Zhang M; Liu X; Zhang H; Huang Y; Li J; Bao J; Wang J; Du J; Guan T; Su L
    Front Genet; 2023; 14():1066808. PubMed ID: 37152994
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy.
    Rodríguez-Sevilla JJ; Fernández-Rodríguez C; Bento L; Diez-Feijóo R; Pinzón S; Gibert J; Fernández-Ibarrondo L; Lafuente M; Ferrer A; Sánchez-González B; Gimeno E; Sainz J; Ramos R; García JF; Colomo L; Bellosillo B; Gutiérrez A; Salar A
    Blood Adv; 2023 Apr; 7(8):1606-1614. PubMed ID: 36260737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
    Watanabe T; Matsuno Y; Wakabayashi M; Maruyama D; Yamamoto K; Kubota N; Shimada K; Asagoe K; Yamaguchi M; Ando K; Ogura M; Kuroda J; Suehiro Y; Tsukasaki K; Tobinai K; Nagai H
    Hematol Oncol; 2024 May; 42(3):e3272. PubMed ID: 38595316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
    Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
    Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
    Mir F; Mattiello F; Grigg A; Herold M; Hiddemann W; Marcus R; Seymour JF; Bolen CR; Knapp A; Nielsen T; Casulo C
    Am J Hematol; 2020 Dec; 95(12):1503-1510. PubMed ID: 32815559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
    Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
    Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.
    Lockmer S; Ren W; Brodtkorb M; Østenstad B; Wahlin BE; Pan-Hammarström Q; Kimby E
    Br J Haematol; 2020 Jan; 188(2):259-267. PubMed ID: 31423576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
    Casulo C; Dixon JG; Le-Rademacher J; Hoster E; Hochster HS; Hiddemann W; Marcus R; Kimby E; Herold M; Sebban C; Gyan E; Foon K; Nielsen T; Vitolo U; Salles GA; Shi Q; Flowers CR
    Blood; 2022 Mar; 139(11):1684-1693. PubMed ID: 34614146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
    Muntañola A; Mozas P; Mercadal S; Huguet M; Bobillo S; Bastos-Oreiro M; Jiménez-Ubieto A; Rovira J; Rivero A; Tolosa C; Luizaga L; de Villambrosia SG; Novelli S; Caballero D; Salar A; Alonso-Álvarez S; Magnano L; Gutiérrez NC; Sancho JM; López-Guillermo A;
    Br J Haematol; 2023 Feb; 200(3):306-314. PubMed ID: 36261137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.
    O'Shea D; O'Riain C; Taylor C; Waters R; Carlotti E; Macdougall F; Gribben J; Rosenwald A; Ott G; Rimsza LM; Smeland EB; Johnson N; Campo E; Greiner TC; Chan WC; Gascoyne RD; Wright G; Staudt LM; Lister TA; Fitzgibbon J
    Blood; 2008 Oct; 112(8):3126-9. PubMed ID: 18628487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
    Tobin JWD; Keane C; Gunawardana J; Mollee P; Birch S; Hoang T; Lee J; Li L; Huang L; Murigneux V; Fink JL; Matigian N; Vari F; Francis S; Kridel R; Weigert O; Haebe S; Jurinovic V; Klapper W; Steidl C; Sehn LH; Law SC; Wykes MN; Gandhi MK
    J Clin Oncol; 2019 Dec; 37(34):3300-3309. PubMed ID: 31461379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
    Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors JM; Gascoyne RD; Hiddemann W; Unterhalt M; Weinstock DM; Weigert O
    Blood; 2016 Aug; 128(8):1112-20. PubMed ID: 27418643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The clinical features, survival analysis, and geriatric assessment of 85 patients with follicular lymphoma: a single-center study].
    Yin JJ; Qian L; Bai JF; Feng R; Li JT; Wang T; Zhang CL; Liu H
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):233-241. PubMed ID: 38716594
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research Network.
    Crouch S; Painter D; Barrans SL; Roman E; Beer PA; Cooke SL; Glover P; Van Hoppe SJL; Webster N; Lacy SE; Ruiz C; Campbell PJ; Hodson DJ; Patmore R; Burton C; Smith A; Tooze RM
    Blood Adv; 2022 Nov; 6(21):5716-5731. PubMed ID: 35363872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
    Ye X; Fan X; Cui R; Mu J; Liu M; Lyu C; Li Y; Chen L; Zhang J; Li X; Wang J; Mou N; Deng Q
    Ann Hematol; 2023 Jul; 102(7):1789-1799. PubMed ID: 37171599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of age on clinical risk scores in follicular lymphoma.
    Alig S; Jurinovic V; Pastore A; Haebe S; Schmidt C; Zoellner AK; Dreyling M; Unterhalt M; Hoster E; Hiddemann W; Weigert O
    Blood Adv; 2019 Apr; 3(7):1033-1038. PubMed ID: 30940638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. m7FLIPI and targeted sequencing in high-risk follicular lymphoma.
    Sorigue M; Oliveira A; Mercadal S; Tapia G; Climent F; Perez-Roca L; Lorences I; Domingo-Domenech E; Cabezon M; Navarro JT; Gonzalez-Barca E; Zamora L; Ribera JM; Sureda A; Armengol MP; Sancho JM
    Hematol Oncol; 2019 Dec; 37(5):564-568. PubMed ID: 31475375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China.
    Gao F; Zhang T; Liu X; Qu Z; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Wang X; Zhang H
    Front Oncol; 2022; 12():863021. PubMed ID: 36185179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.